Company / Operating Cash Flow
MBX Biosciences, Inc. Operating Cash Flow History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$54.7M
FY2024
5-year range
-$54.7M / -$32.0M
FY2023-FY2024
Trend
-71.0%
vs FY2023
Sector context
#97 of 216
Health Care
What the data says
At -$55M, MBX Biosciences, Inc.'s operating cash flow ranks #97 of 216 in the Health Care sector.
Based on SEC 10-K filings.
-$55M in FY2024.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#97 of 216 in Health CareTop 45% of 216This company -$54.7M Sector average $658.7M
▼
-108.3% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 71.0% year-over-year.
- Ranks #97 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 9.64 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$54.7M | -71.0% |
| FY2023 | -$32.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026